CINCINNATI, March 17 Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that it has entered into a new $35 million secured revolving credit facility as of March 15, 2010 with JPMorgan Chase Bank N.A., as administrative agent, which replaces the Company's previous revolving credit facility. The new facility contains provisions allowing the Company to request an increase of up to $15 million in capacity, subject to the consent of the current lender or additional lenders. The new revolving facility matures on January 15, 2012 and is automatically extended to March 31, 2015 if certain conditions are met related to the Company's convertible notes.
Advertisement
Commenting on the transaction, Keith Cheesman, Senior Vice President and Chief Financial Officer said, "We are very pleased with this new facility and with having JPMorgan Chase serve as our agent. This new facility offers more flexible terms and conditions, together with a duration and a capacity, all of which will better position us to execute against our long-term strategic plans."
Advertisement
Under the terms of this new facility, the Company may borrow in U.S. dollars or other globally-traded currencies, including the Euro and the Pound Sterling. The new credit agreement contains various affirmative and negative covenants including limitations on capital expenditures, investments, indebtedness, acquisitions and asset sales outside the ordinary course of business. The new agreement also contains various financial covenants including a total leverage ratio, a senior leverage ratio and an interest coverage ratio. Additional details about the new credit facility are available in the Company's most recently filed Annual Report on Form 10-K.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
Forward-Looking Statements
Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995 and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated benefits of the new revolving credit facility, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC. All information in this press release is current as of March 17, 2010. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
SOURCE Kendle International Inc.
